Can Hormonal IUDs Worsen Anxiety?
Yes, levonorgestrel-releasing intrauterine systems (LNG-IUS) are associated with increased anxiety symptoms, with evidence showing an 18% increased risk compared to non-hormonal IUDs.
Evidence for Anxiety Risk
The strongest evidence comes from a large UK cohort study demonstrating that women using LNG-IUS had a statistically significant increased risk of new-onset anxiety compared to those using non-hormonal (copper) IUDs, with a hazard ratio of 1.18 (95% CI 1.08-1.29) 1. This same study also found increased sleep problems (HR 1.22,95% CI 1.08-1.38) among LNG-IUS users 1.
Dose-Response Relationship
Recent high-quality evidence reveals a dose-dependent relationship between levonorgestrel exposure and psychiatric symptoms:
- High-dose (52 mg) LNG-IUS: Associated with the highest depression risk at 30.8 per 1,000 person-years 2
- Medium-dose (19.5 mg) LNG-IUS: 23% lower risk compared to high-dose (adjusted rate ratio 0.77) 2
- Low-dose (13.5 mg) LNG-IUS: 15% lower risk compared to high-dose (adjusted rate ratio 0.85) 2
A 2024 study confirmed this dose-response pattern, showing 1-year depression risks of 1.21% for low-dose, 1.46% for medium-dose, and 1.84% for high-dose LNG-IUS 3.
Clinical Manifestations
Case reports document severe psychiatric reactions including:
- Anxiety and panic attacks developing within weeks of insertion 4
- Symptoms occurring even after replacement of a previously well-tolerated device 4
- Complete remission of anxiety symptoms following device removal 4, 5
A systematic review of 22 studies found that while depression was most commonly reported, anxiety was also documented as a psychiatric adverse effect of LNG-IUS 6.
Biological Mechanism
Animal studies provide mechanistic insight: long-term levonorgestrel administration decreases allopregnanolone levels by 75% in cerebral cortex and 55% in hippocampus, alters GABA-A receptor subunit expression, and induces anxiety-like behavior 7. These neurosteroid changes specifically result from the levonorgestrel component, not the estrogen component of hormonal contraceptives 7.
Recent proteomic analysis shows that levonorgestrel treatment of human neural progenitor cells induces changes in pathways related to inflammation, oxidative stress, and cell death—all mechanisms implicated in depression and anxiety disorders 8.
Clinical Recommendations
When counseling patients about LNG-IUS:
- Inform all patients that anxiety is a recognized adverse effect with an approximately 18% increased risk 1
- Explain that psychiatric symptoms can occur even with replacement devices, not just initial insertion 4
- Consider preferentially recommending low-dose LNG-IUS (13.5 mg or 19.5 mg) over high-dose (52 mg) for contraceptive purposes, as they carry lower psychiatric risk 2, 3
- Document this discussion in informed consent 4
If anxiety develops after LNG-IUS insertion:
- Consider the device as a potential cause, particularly if symptoms began within weeks to months of insertion 4
- Removal of the device should be offered if the patient desires it, with prompt counseling on alternative contraceptive methods 9
- Symptom resolution typically occurs after removal, often within weeks to months 4, 5
Important Caveats
The evidence shows baseline differences between women choosing hormonal versus non-hormonal IUDs, making definitive causal conclusions challenging 1. However, the dose-response relationship 2, 3, temporal association with insertion 4, symptom resolution after removal 4, 5, and biological plausibility 7, 8 all support a causal link.
Note: The FDA labeling for levonorgestrel emergency contraception 10 is not relevant to this question about intrauterine devices, as emergency contraception involves different dosing, duration, and systemic exposure patterns.